Form 8-K - Current report:
SEC Accession No. 0001171843-25-001513
Filing Date
2025-03-18
Accepted
2025-03-18 07:30:11
Documents
15
Period of Report
2025-03-18
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_031825.htm   iXBRL 8-K 14879
2 PRESS RELEASE exh_991.htm EX-99.1 50812
  Complete submission text file 0001171843-25-001513.txt   273210

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20190101.xsd EX-101.SCH 3003
4 XBRL DEFINITION FILE gnw-20190101_def.xml EX-101.DEF 25598
5 XBRL LABEL FILE gnw-20190101_lab.xml EX-101.LAB 34011
6 XBRL PRESENTATION FILE gnw-20190101_pre.xml EX-101.PRE 22139
17 EXTRACTED XBRL INSTANCE DOCUMENT f8k_031825_htm.xml XML 3425
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40908 | Film No.: 25746496
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)